more

Pfizer (PFE)

(Real Time Quote from BATS)

$28.86 USD

-0.23 (-0.79%)

Updated Sep 30, 2024 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on January 31,2023

Pfizer (PFE) delivered earnings and revenue surprises of 10.68% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Markets Close at Session Lows Ahead of Massive Data, Fed

by Mark Vickery Published on January 30,2023

The Dow dropped -260 points, -0.77%, and it was the outperformer. The S&P 500 was -1.30% on the day, while the Nasdaq sank -227 points, -1.96%.

The Zacks Analyst Blog Highlights Pfizer/BioNTech, Moderna and Novavax

by Zacks Equity Research Published on January 30,2023

Pfizer/BioNTech, Moderna and Novavax are included in this Analyst Blog.

pharmaceuticals

Novavax (NVAX) COVID Jab Aids Growth, Overdependence a Challenge (revised)

by Zacks Equity Research Published on January 27,2023

Despite being one of the few authorized COVID-19 vaccine makers in the United States, Novavax's (NVAX) vaccine struggles for market share.

Bristol-Myers (BMY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research Published on January 27,2023

Investors are likely to focus on the demand for Eliquis and Opdivo, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.

FDA Panel Endorses Simplification of COVID-19 Vaccine Strategy

by Zacks Equity Research Published on January 27,2023

An FDA advisory committee unanimously votes in favor of using the same COVID-19 vaccine strain composition for primary series and booster doses.